|
Revalesio Presenting RNS60 Data at ACAAI
Drug Discovery & Development ACAAI (American College of Allergy, Asthma and Immunology) is a professional association with more than 5000 members devoted to the specialty of allergy and immunology. In this first in man asthma study, RNS60 demonstrated therapeutic benefit and … |
View full post on asthma – Google News